Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Executive Summary
Lilly hopes to be ready for a re-inspection of its intramuscular Zyprexa production facility in mid-May, ahead of the late June user fee deadline for a decision on the new formulation of the antipsychotic.
You may also be interested in...
FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround
Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company
FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround
Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company
Lilly Expects Full GMP Inspection After Upgrades To “Building 105”
Lilly is planning to shut down its "Building 105" manufacturing facility in 2004 to make GMP upgrades, CEO Sidney Taurel said during a Dec. 3 analyst dinner in New York